Eli Lilly (LLY) Retained Earnings (2009 - 2026)

Eli Lilly has reported Retained Earnings for 18 years, with the latest figure at $29.5 billion in Q1 2026.

• For the quarter ending Q1 2026, Retained Earnings rose 881.91% year-over-year to $29.5 billion; the trailing twelve-month figure through Mar 2026 stood at $29.5 billion (up 881.91% YoY), and the FY2025 full-year result was -$2.9 billion, up 33.36% from the prior year.
• Retained Earnings for Q1 2026 stood at $29.5 billion, up from -$2.9 billion in the prior quarter.
• The five-year high for Retained Earnings was $29.5 billion in Q1 2026, with the low at -$4.4 billion in Q2 2024.
• Historically, Retained Earnings has averaged $2.5 billion across 5 years, with a median of -$3.8 billion in 2025.
• Annual changes were most pronounced in 2023 — Retained Earnings tumbled 144.28% — and 2026, when it jumped 881.91%.
• Eli Lilly's Retained Earnings stood at $10.0 billion in 2022, then sank by 143.09% to -$4.3 billion in 2023, then increased by 0.12% to -$4.3 billion in 2024, then surged by 33.36% to -$2.9 billion in 2025, then surged by 1124.79% to $29.5 billion in 2026.
• The last three Retained Earnings figures came in at $29.5 billion (Q1 2026), -$2.9 billion (Q4 2025), and -$3.2 billion (Q3 2025), per Business Quant data.